(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 10.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Vanda Pharmaceuticals's revenue in 2024 is $192,640,000.On average, 1 Wall Street analysts forecast VNDA's revenue for 2024 to be $10,817,049,812, with the lowest VNDA revenue forecast at $10,817,049,812, and the highest VNDA revenue forecast at $10,817,049,812.
In 2025, VNDA is forecast to generate $10,086,323,575 in revenue, with the lowest revenue forecast at $10,086,323,575 and the highest revenue forecast at $10,086,323,575.